DOP2013000273A - Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa - Google Patents
Compuestos novedosos como inhibidores de diacilglicerol aciltransferasaInfo
- Publication number
- DOP2013000273A DOP2013000273A DO2013000273A DO2013000273A DOP2013000273A DO P2013000273 A DOP2013000273 A DO P2013000273A DO 2013000273 A DO2013000273 A DO 2013000273A DO 2013000273 A DO2013000273 A DO 2013000273A DO P2013000273 A DOP2013000273 A DO P2013000273A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- dgat
- inhibitors
- diacilglicerol
- aciltransferasa
- new compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1451DE2011 | 2011-05-20 | ||
| US201161495049P | 2011-06-09 | 2011-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2013000273A true DOP2013000273A (es) | 2014-04-15 |
Family
ID=47217644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2013000273A DOP2013000273A (es) | 2011-05-20 | 2013-11-20 | Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9242929B2 (https=) |
| EP (1) | EP2723332B1 (https=) |
| JP (1) | JP5893724B2 (https=) |
| KR (1) | KR20140033426A (https=) |
| CN (1) | CN103687595B (https=) |
| AU (1) | AU2012259042B2 (https=) |
| CA (1) | CA2836666A1 (https=) |
| CO (1) | CO6811853A2 (https=) |
| CR (1) | CR20130603A (https=) |
| DO (1) | DOP2013000273A (https=) |
| EA (1) | EA023239B1 (https=) |
| ES (1) | ES2572261T3 (https=) |
| IL (1) | IL229487A0 (https=) |
| MA (1) | MA35398B1 (https=) |
| MX (1) | MX2013013565A (https=) |
| PE (1) | PE20140618A1 (https=) |
| PH (1) | PH12013502403A1 (https=) |
| SG (1) | SG194976A1 (https=) |
| WO (1) | WO2012162127A1 (https=) |
| ZA (1) | ZA201308569B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013341115B2 (en) * | 2012-11-09 | 2016-07-14 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
| WO2014081995A1 (en) * | 2012-11-23 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
| WO2022026380A1 (en) * | 2020-07-29 | 2022-02-03 | Board Of Regents, The University Of Texas System | Urea inhibitors of micro-rna |
| CN111747876B (zh) * | 2020-08-03 | 2023-05-26 | 万华化学集团股份有限公司 | 一种氧化角黄素制备虾青素的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006045209A (ja) * | 2004-07-02 | 2006-02-16 | Sankyo Co Ltd | ウレア誘導体 |
| WO2006004200A1 (ja) * | 2004-07-02 | 2006-01-12 | Sankyo Company, Limited | ウレア誘導体 |
| KR20080000652A (ko) * | 2005-04-19 | 2008-01-02 | 바이엘 파마슈티칼스 코포레이션 | 아릴 알킬산 유도체 및 그의 용도 |
| EP2402320A1 (en) | 2006-03-31 | 2012-01-04 | Novartis AG | Anorectic agents |
| GB0625654D0 (en) * | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| WO2008099221A1 (en) * | 2007-02-15 | 2008-08-21 | Prosidion Limited | Amide and urea derivatives for the treatment of metabolic diseases |
| JP2008255024A (ja) * | 2007-04-02 | 2008-10-23 | Banyu Pharmaceut Co Ltd | ビアリールアミン誘導体 |
| US8394823B2 (en) * | 2008-04-11 | 2013-03-12 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as DGAT1 inhibitors |
| CA2790390A1 (en) | 2009-08-28 | 2011-03-03 | Daiichi Sankyo Company, Limited | Novel tetrahydroisoquinoline compounds |
| JP2011088889A (ja) * | 2009-09-24 | 2011-05-06 | Daiichi Sankyo Co Ltd | 新規テトラヒドロイソキノリン誘導体を含有する医薬 |
| BR112012016178A2 (pt) * | 2009-12-31 | 2015-10-06 | Piramal Healthcare Ltd | inibidores de diacilglicerol aciltransferase |
| US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
-
2012
- 2012-05-18 CN CN201280035285.1A patent/CN103687595B/zh not_active Expired - Fee Related
- 2012-05-18 US US14/118,913 patent/US9242929B2/en not_active Expired - Fee Related
- 2012-05-18 CA CA 2836666 patent/CA2836666A1/en not_active Abandoned
- 2012-05-18 PH PH1/2013/502403A patent/PH12013502403A1/en unknown
- 2012-05-18 KR KR1020137033506A patent/KR20140033426A/ko not_active Withdrawn
- 2012-05-18 SG SG2013084603A patent/SG194976A1/en unknown
- 2012-05-18 AU AU2012259042A patent/AU2012259042B2/en not_active Ceased
- 2012-05-18 ES ES12789372T patent/ES2572261T3/es active Active
- 2012-05-18 PE PE2013002520A patent/PE20140618A1/es not_active Application Discontinuation
- 2012-05-18 WO PCT/US2012/038520 patent/WO2012162127A1/en not_active Ceased
- 2012-05-18 JP JP2014511574A patent/JP5893724B2/ja not_active Expired - Fee Related
- 2012-05-18 MX MX2013013565A patent/MX2013013565A/es not_active Application Discontinuation
- 2012-05-18 EA EA201391724A patent/EA023239B1/ru not_active IP Right Cessation
- 2012-05-18 EP EP12789372.5A patent/EP2723332B1/en active Active
-
2013
- 2013-11-14 ZA ZA2013/08569A patent/ZA201308569B/en unknown
- 2013-11-18 IL IL229487A patent/IL229487A0/en unknown
- 2013-11-19 CO CO13271927A patent/CO6811853A2/es active IP Right Grant
- 2013-11-20 DO DO2013000273A patent/DOP2013000273A/es unknown
- 2013-11-20 CR CR20130603A patent/CR20130603A/es unknown
- 2013-12-13 MA MA36565A patent/MA35398B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103687595A (zh) | 2014-03-26 |
| EP2723332A1 (en) | 2014-04-30 |
| EA023239B1 (ru) | 2016-05-31 |
| US9242929B2 (en) | 2016-01-26 |
| EP2723332B1 (en) | 2016-03-02 |
| ES2572261T3 (es) | 2016-05-31 |
| CN103687595B (zh) | 2017-05-24 |
| KR20140033426A (ko) | 2014-03-18 |
| WO2012162127A1 (en) | 2012-11-29 |
| US20150307445A1 (en) | 2015-10-29 |
| PH12013502403A1 (en) | 2018-04-11 |
| CO6811853A2 (es) | 2013-12-16 |
| PE20140618A1 (es) | 2014-06-05 |
| SG194976A1 (en) | 2013-12-30 |
| JP5893724B2 (ja) | 2016-03-23 |
| JP2014525895A (ja) | 2014-10-02 |
| MA35398B1 (fr) | 2014-09-01 |
| CR20130603A (es) | 2014-09-09 |
| CA2836666A1 (en) | 2012-11-29 |
| AU2012259042A1 (en) | 2013-04-18 |
| MX2013013565A (es) | 2014-01-08 |
| ZA201308569B (en) | 2014-07-30 |
| EP2723332A4 (en) | 2014-10-15 |
| IL229487A0 (en) | 2014-01-30 |
| AU2012259042B2 (en) | 2015-06-11 |
| EA201391724A1 (ru) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2013000272A (es) | Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa | |
| UY32919A (es) | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos | |
| BR112012032579A2 (pt) | "terapia de diabetes" | |
| ECSP13013068A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
| ECSP13013024A (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
| BR112012004696B8 (pt) | composto modulador da atividade de tlr, seu uso, composição farmacêutica, medicamento, kit e combinação | |
| DK2459216T3 (da) | Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer | |
| BR112014016165A2 (pt) | compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido | |
| BR112016017193A2 (pt) | Derivados de insulina, seus usos, e composição farmacêutica | |
| MX347471B (es) | Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas. | |
| BR112014012230A2 (pt) | fralda de vestir descartável de tamanho pequeno | |
| PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| BR112012032721A2 (pt) | compostos heterocíclicos, sua preparação e sua aplicação terapêutica | |
| MX2013012661A (es) | Compuestos de piridazina biciclicos como inhibidores pim. | |
| AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
| BR112015006656A8 (pt) | composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos | |
| DOP2013000273A (es) | Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa | |
| CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. | |
| BR112015010196A2 (pt) | métodos de tratar doença do fígado | |
| BR112015010223A2 (pt) | compostos tricíclicos para o uso no tratamento e/ou controle de obesidade | |
| BR112012028906A2 (pt) | polimorfos de benzoato de alogliptina | |
| PE20150967A1 (es) | Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa | |
| MX2015001677A (es) | Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacion. | |
| IN2013MU01154A (https=) | ||
| IN2013MU01155A (https=) |